MA-MARIANA-ONCO/NOVARTIS
2.5.2024 13:01:28 CEST | Business Wire | Press release
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.
Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer.
“Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology. “In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline. Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside. Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.”
“This acquisition of Mariana Oncology brings to Novartis phenomenal talent and new capabilities in radioligand therapeutic research that complement our wide-ranging internal research and drug discovery efforts, in addition to our translational and clinical development capabilities,” said Shiva Malek, PhD, Global Head of Oncology for Biomedical Research at Novartis. “This is an ideal pairing, and we are thrilled to continue to do pioneering science together, translating RLT discovery into clinical development to deliver transformative therapies to patients.”
Mariana was founded in 2021 by Atlas Venture, Access Biotechnology and RA Capital Management, and has raised additional funds from other top investors including DeepTrack Capital and Forbion.
The transaction is subject to customary closing conditions.
Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.
About Mariana Oncology
Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment – targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana is comprised of some of the world’s leading experts in radiopharmaceutical science and manufacturing who together are pioneering innovations in end-to-end discovery, development and delivery of radioligand therapeutics. The company has developed a portfolio of novel RLTs designed to target a broad range of difficult-to-treat cancers. Mariana’s lead program, MC-339, is an actinium-based radioligand therapeutic being investigated to treat small cell lung cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502315526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Activates Data for the Enterprise9.3.2026 14:00:00 CET | Press release
New platform innovations activate contextual data to power production-scale enterprise AI, with a new European platform instance for localized control Boomi™, the data activation company, today announced new capabilities within the Boomi Enterprise Platform. Data activation brings data to life across systems and processes, delivering it with the right context and timing to power everything from AI to BI. The Boomi Enterprise Platform, the foundation that puts data in motion, now adds new semantic context to help AI agents operate on grounded business realities, expands governed SAP data movement with change data capture, enhances transparency and oversight across agentic workflows, and introduces a dedicated European platform instance for localized data control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309682526/en/ Boomi Activates Data for the Enterprise “Last year, Boomi helped enterprises move from experimentatio
Thredd Accelerates in 2026 with its Global Platform and Delivering Enterprise-Scale Outcomes9.3.2026 14:00:00 CET | Press release
Thredd, the AI-first issuer processing platform, today announced a major acceleration phase for 2026, marked by the appointment of Marilyn McDonald as Chief Technology Officer and the promotion of Ryan Dew to Chief Product Officer. Thredd has never been in a stronger position. A fully cloud-native version of its global platform is live in the United States, with end-to-end credit capabilities launching in the coming months alongside a state-of-the-art debit platform and modern unified ledger. Marilyn McDonald joins as CTO to lead the next phase of enterprise-scale execution. She succeeds Edwin Poot, who helped lead the modernisation of Thredd’s architecture and technology stack, laying the foundation for cloud-native and agentic growth. Marilyn brings global transformation experience from senior roles at Citigroup, Mastercard, Expedia Group and StubHub. Her focus is on strengthening operational readiness, bank-grade delivery, enterprise execution and continuous resilience as Thredd sca
MariaDB to Acquire GridGain: Architecting the Real-Time Foundation for the Agentic Enterprise9.3.2026 14:00:00 CET | Press release
Strategic acquisition unites MariaDB’s mission-critical relational database with GridGain’s extreme in-memory speed to power the next generation of AI applications MariaDB plc today announced that it has entered into a definitive agreement to acquire GridGain Systems, Inc., the pioneer of in-memory computing and creator of open source Apache Ignite. By merging MariaDB’s AI-ready relational database with GridGain’s scalable, in-memory power, MariaDB is setting a new industry standard: sub-millisecond data infrastructure for the agentic era. Closing the AI Latency Gap As enterprises move beyond passive chatbots toward agentic AI – autonomous systems that reason, plan and execute tasks – they are quickly becoming limited by traditional data architectures. AI agents require real-time access to massive datasets with zero friction. This acquisition bridges that gap by fusing: MariaDB’s reliability: Proven, ACID-compliant transactional integrity for the world’s most sensitive data, with nativ
Safe Software Announces the Peak of Data and AI 2027, a Premier Global Conference, in London, UK9.3.2026 14:00:00 CET | Press release
Safe Software (Safe) officially announced today the return of its global user conference, the Peak of Data and AI, taking place March 9–11, 2027, at the QEII Centre in London, UK. A Partner Summit will kick off the event on March 8, 2027, bringing together Safe’s global partner community ahead of the main conference. Hosted every two years, the Peak of Data and AI has evolved from Safe Software’s long-running user conference into a premier global event for data and AI professionals. The conference alternates between North America and international locations, with previous events held in Bonn, Germany (2023) and Seattle, Washington (2025). “At the Peak of Data and AI, we bring together the people who are shaping how organizations use data to drive real-world outcomes,” said Don Murray, CEO of Safe Software. “With London as our host city in 2027, we’re excited to connect with the global community to learn, listen, and share what’s next for data and AI.” The three-day conference will feat
Quectel Modules Demonstrate Compliance Readiness for EU Cyber Resilience Act Regulatory Requirements9.3.2026 13:45:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today reiterates that its cybersecurity program for its module portfolio supports compliance with the European Union’s Cyber Resilience Act (CRA), ahead of the 11 September 2026 deadline. Quectel’s best practice product security ensures customers can meet the CRA’s mandatory requirements for security by design, SBOM availability and vulnerability disclosure and incident reporting, reinforcing Quectel’s commitment to delivering secure, future-ready IoT solutions for the European and global markets. Quectel has worked closely with Finite State, a leader in connected device and software supply chain security, to ensure Quectel’s product portfolio is both secure and compliant for the EU CRA and other industry standards globally. The partnership reinforces a clear focus on transparency, regulatory alignment and a commitment to maintaining industry-leading cybersecurity standards. “Finite State has been Quectel’s third p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom